OSE Immunotherapeutics Unveils First-in-Class FPR2 Agonist for Chronic Inflammation at AAI 2026
Event summary
- OSE Immunotherapeutics will present a novel FPR2 agonist monoclonal antibody at the AAI 2026 Meeting on April 17, 2026.
- The antibody targets the FPR2 receptor to trigger resolution of chronic inflammation by limiting neutrophil recruitment and reprogramming macrophages.
- Aurore Morello, PhD, Chief Scientific Officer, will deliver the oral presentation in Boston, Massachusetts.
- The approach aims to restore physiological balance rather than suppress immune cells, addressing unmet medical needs in chronic inflammatory diseases.
The big picture
OSE Immunotherapeutics' presentation at AAI 2026 highlights a strategic shift toward resolution biology in treating chronic inflammation, a growing area with significant unmet medical needs. The company's focus on activating natural inflammation-resolution mechanisms differentiates it from current treatments that primarily suppress immune cells. This approach could open new therapeutic opportunities and build long-term value in the immuno-inflammation space.
What we're watching
- Clinical Validation
- Whether preclinical efficacy translates into clinical success for the FPR2 agonist antibody.
- Market Differentiation
- How OSE's resolution biology approach will compete with existing chronic inflammation treatments.
- Partnership Potential
- The pace at which OSE can secure collaborations or licensing deals for this novel therapy.
Related topics